Literature DB >> 22094190

Chronic widespread pain: from peripheral to central evolution.

Piercarlo Sarzi-Puttini1, Fabiola Atzeni, Philip J Mease.   

Abstract

Chronic pain can be classified as localised, regional or widespread, and its high prevalence in the general population seems to increase with age. The majority of cases present with musculoskeletal pain. The conditions associated with chronic widespread pain (CWP) are highly burdensome as their characteristic symptoms may include multifocal pain, fatigue, insomnia, memory difficulties and a higher rate of concomitant mood disorders. After many years of debate, it is still unclear whether CWP (central sensitisation) is an entirely explainable neurotransmitter-related process or is partially or totally due to individual cognitive experiences and evaluations. The two models (neurochemical and biopsychosocial) also affect our ability to find therapeutic answers.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094190     DOI: 10.1016/j.berh.2011.04.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  15 in total

1.  Prevalence of the fibromyalgia phenotype in patients with spine pain presenting to a tertiary care pain clinic and the potential treatment implications.

Authors:  Chad M Brummett; Jenna Goesling; Alex Tsodikov; Taha S Meraj; Ronald A Wasserman; Daniel J Clauw; Afton L Hassett
Journal:  Arthritis Rheum       Date:  2013-12

2.  [Etiopathogenetic aspects of somatoform disorders].

Authors:  M Noll-Hussong; H Gündel
Journal:  Nervenarzt       Date:  2012-09       Impact factor: 1.214

3.  An Evaluation of Central Sensitization in Patients With Sickle Cell Disease.

Authors:  Claudia M Campbell; Gyasi Moscou-Jackson; C Patrick Carroll; Kasey Kiley; Carlton Haywood; Sophie Lanzkron; Matthew Hand; Robert R Edwards; Jennifer A Haythornthwaite
Journal:  J Pain       Date:  2016-02-16       Impact factor: 5.820

Review 4.  Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain.

Authors:  Lars Arendt-Nielsen; Søren T Skou; Thomas A Nielsen; Kristian K Petersen
Journal:  Curr Osteoporos Rep       Date:  2015-08       Impact factor: 5.096

5.  Effects of 15 consecutive cryotherapy sessions on the clinical output of fibromyalgic patients.

Authors:  Lorenzo Bettoni; Felice Giulio Bonomi; Viviana Zani; Luigia Manisco; Annamaria Indelicato; Patrizia Lanteri; Giuseppe Banfi; Giovanni Lombardi
Journal:  Clin Rheumatol       Date:  2013-05-02       Impact factor: 2.980

Review 6.  Pain in Women: A Perspective Review on a Relevant Clinical Issue that Deserves Prioritization.

Authors:  Roberto Casale; Fabiola Atzeni; Laura Bazzichi; Giovanna Beretta; Elisabetta Costantini; Paola Sacerdote; Cristina Tassorelli
Journal:  Pain Ther       Date:  2021-03-15

Review 7.  Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.

Authors:  Anthony Tucker-Bartley; Jordan Lemme; Andrea Gomez-Morad; Nehal Shah; Miranda Veliu; Frank Birklein; Claudia Storz; Seward Rutkove; David Kronn; Alison M Boyce; Eduard Kraft; Jaymin Upadhyay
Journal:  Neurosci Biobehav Rev       Date:  2021-02-10       Impact factor: 9.052

8.  Hyperbaric oxygen therapy can diminish fibromyalgia syndrome--prospective clinical trial.

Authors:  Shai Efrati; Haim Golan; Yair Bechor; Yifat Faran; Shir Daphna-Tekoah; Gal Sekler; Gregori Fishlev; Jacob N Ablin; Jacob Bergan; Olga Volkov; Mony Friedman; Eshel Ben-Jacob; Dan Buskila
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

9.  Widespread pain - do pain intensity and care-seeking influence sickness absence? - A population-based cohort study.

Authors:  Søren Mose; David Høyrup Christiansen; Jens Christian Jensen; Johan Hviid Andersen
Journal:  BMC Musculoskelet Disord       Date:  2016-05-04       Impact factor: 2.362

10.  Predictors of fibromyalgia: a population-based twin cohort study.

Authors:  Ritva A Markkula; Eija A Kalso; Jaakko A Kaprio
Journal:  BMC Musculoskelet Disord       Date:  2016-01-15       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.